People In The News

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics said this week that Brian Markison has become an observer to the company's board of directors and that he will become a director at the firm upon approval. Markison currently is chairman and CEO of King Pharmaceuticals, where he led the company through to its recently announced acquisition by Pfizer, and before that he was at Bristol-Myers Squibb, where he served as president of BMS Oncology/Virology and Oncology Therapeutics Network.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.